Klabid ER Tablet (Extended Release) 500 mg
Klabid ER Tablet (Extended Release) 500 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
Klabid ER Tablet (Extended Release) 500 mg is a macrolide antibiotic. It acts by inhibiting microsomal protein synthesis by binding to the 50S subunit of the bacterial ribosome. Klabid ER Tablet (Extended Release) 500 mg is active against most gram-positive bacteria, Chlamydia, some gram-negative bacteria and Mycoplasmas.
Klabid ER Tablet (Extended Release) 500 mg is a macrolide antibiotic whose spectrum of activity includes many gram-positive (Staphylococcus aureus, S. pneumoniae, and S. pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis), many anaerobic bacteria, some mycobacteria, and some other organisms including Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma, and Borrelia. Other aerobic bacteria that clarithromycin has activity against include C. pneumoniae and M. pneumoniae. Klabid ER Tablet (Extended Release) 500 mg has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Klabid ER Tablet (Extended Release) 500 mg is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.
| Trade Name | Klabid ER Tablet (Extended Release) 500 mg |
| Availability | Prescription only |
| Generic | Clarithromycin |
| Clarithromycin Other Names | 6-O-methyl erythromycin, 6-O-methylerythromycin, 6-O-methylerythromycin A, Clarithromycin, Clarithromycina, Clarithromycine, Clarithromycinum, Claritromicina |
| Related Drugs | amoxicillin, prednisone, omeprazole, pantoprazole, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin |
| Weight | 500 mg |
| Type | Tablet (Extended Release) |
| Formula | C38H69NO13 |
| Weight | Average: 747.9534 Monoisotopic: 747.476891299 |
| Protein binding | ~ 70% protein bound |
| Groups | Approved |
| Therapeutic Class | Macrolides |
| Manufacturer | UniMed UniHealth Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
- LRTIs for example, acute and chronic bronchitis and pneumonia.
- URTIs for example, sinusitis and pharyngitis.
- Community-acquired pneumonia, atypical pneumonia
- Skin and soft tissue infection
- Adjunct in the treatment of duodenal ulcers to eradicate of H. pylori
Klabid ER Tablet (Extended Release) 500 mg is also used to associated treatment for these conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Infective Endocarditis, Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Streptococcal tonsillitis, Uncomplicated skin and subcutaneous tissue bacterial infections
How Klabid ER Tablet (Extended Release) 500 mg works
Klabid ER Tablet (Extended Release) 500 mg is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. Like other macrolides, it then penetrates bacteria cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide synthesis. Klabid ER Tablet (Extended Release) 500 mg also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump.
Dosage
Klabid ER Tablet (Extended Release) 500 mg dosage
Klabid ER Tablet (Extended Release) 500 mg may be given with or without meals.
Adults (12 years or above):
250 mg twice daily for 7 days. Dose may be increased to 500 mg twice daily for up to 14 days in pneumonia or severe infections.
Combination therapy for H. pylori infection:
Klabid ER Tablet (Extended Release) 500 mg 500 mg (two 250 mg tablets or one 500 mg tablet) twice daily in combination with Amoxicillin 1000 mg twice daily and Omeprazole 20 mg twice daily should be continued for 10 days.
Children:
The usual recommended daily dosage is 15 mg/kg in 2 divided doses for 10 days.
Approximate Calculation of dose:
1. For 9kg body weight 2.5ml 12 hourly for 10 days
2. For 17kg body weight 5ml 12 hourly for 10 days
3. For 25kg body weight 7.5ml 12 hourly for 10 days
4. For 33kg body weight 10ml 12 hourly for 10 days
Direction for reconstitution of suspension:
Shake the bottle to loosen granules. Add 35 ml of boiled and cooled water with the help of the supplied cup, to the dry granules of the bottle. For ease of preparation, add water to the bottle in two proportions. Shake well after each addition until all the granules is in suspension.
Note: Shake the suspension well before each use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool and dry place, preferably in refrigerator.
This may be given with or without meals.
The usual duration of treatment is 6 to 14 days.
Children older than 12 years: As for adults.
Eradication of H. pylori in patients with duodenal ulcers: Adults: The usual duration of treatment is 6 to 14 days.
45 ml of water is to be added to the granules in the bottle and shaken to yield 70 ml of reconstituted suspension. The concentration of clarithromycin in the reconstituted suspension is 125 mg per 5 ml.
Side Effects
The most frequently reported events in adults taking Klabid ER Tablet (Extended Release) 500 mg were diarrhoea (3%), nausea (3%), abnormal taste (3%), dyspepsia (2%), abdominal pain/discomfort (2%), headache (2%) and oral monilia.
Toxicity
Symptoms of toxicity include diarrhea, nausea, abnormal taste, dyspepsia, and abdominal discomfort. Transient hearing loss with high doses has been observed. Pseudomembraneous colitis has been reported with clarithromycin use. Allergic reactions ranging from urticaria and mild skin eruptions to rare cases of anaphylaxis and Stevens-Johnson syndrome have also occurred. Rare cases of severe hepatic dysfunctions also have been reported. Hepatic failure is usually reversible, but fatalities have been reported. Klabid ER Tablet (Extended Release) 500 mg may also cause tooth decolouration which may be removed by dental cleaning. Fetal abnormalities, such as cardiovascular defects, cleft palate and fetal growth retardation, have been observed in animals. Klabid ER Tablet (Extended Release) 500 mg may cause QT prolongation.
Precaution
Caution should be taken in administering this antibiotic to patients with impaired hepatic and renal function. Prolonged or repeated use of Klabid ER Tablet (Extended Release) 500 mg may result in an overgrowth of nonsusceptible bacteria or fungi. If superinfection occurs, Klabid ER Tablet (Extended Release) 500 mg should be discontinued.
Pharmaceutical precaution
Klabid ER Tablet (Extended Release) 500 mg tablet should be stored in a cool and dry place and away from sunlight.
Interaction
Concomitant use of Klabid ER Tablet (Extended Release) 500 mg who are receiving Theophylline may be associated with an increase in serum Theophylline concentrations. Klabid ER Tablet (Extended Release) 500 mg may alter the metabolism of Terfenadine. The effects of digoxin may be potentiated with concomitant administration of Klabid ER Tablet (Extended Release) 500 mg. Klabid ER Tablet (Extended Release) 500 mg resulted in decrease in serum levels of Rifabutin, followed by an increased risk of uveitis.
Food Interaction
- Take with food. Food increases absorption.
[Minor] Grapefruit juice may delay the gastrointestinal absorption of clarithromycin but does not appear to affect the overall extent of absorption or inhibit the metabolism of clarithromycin.
The mechanism of interaction is unknown but may be related to competition for intestinal CYP450 3A4 and In an open-label, randomized, crossover study consisting of 12 healthy subjects, coadministration with grapefruit juice increased the time to reach peak plasma concentration (Tmax) of both clarithromycin and 14-hydroxyclarithromycin (the active metabolite) by 80% and 104%, respectively, compared to water. Other pharmacokinetic parameters were not significantly altered. This interaction is unlikely to be of clinical significance.
Klabid ER Tablet (Extended Release) 500 mg Drug Interaction
Moderate: albuterol / ipratropium, albuterol / ipratropiumMinor: amoxicillin / clavulanate, amoxicillin / clavulanate, esomeprazole, esomeprazoleUnknown: diphenhydramine, diphenhydramine, acetaminophen, acetaminophen, acetaminophen, acetaminophen, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol, cetirizine, cetirizine
Klabid ER Tablet (Extended Release) 500 mg Disease Interaction
Major: colitis, QT prolongationModerate: renal dysfunction, myasthenia gravis
Elimination Route
Klabid ER Tablet (Extended Release) 500 mg is well-absorbed, acid stable and may be taken with food.
Half Life
3-4 hours
Elimination Route
After a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.
Pregnancy & Breastfeeding use
Klabid ER Tablet (Extended Release) 500 mg is not recommended for pregnant women. Breast milk from mothers receiving Klabid ER Tablet (Extended Release) 500 mg should not be given to infants until treatment is completed. Klabid ER Tablet (Extended Release) 500 mg may be used in neonates and children in appropriate doses.
Contraindication
Hypersensitive to Klabid ER Tablet (Extended Release) 500 mg, Erythromycin or any of the macrolide antibiotics. Patients receiving terfenadine who have pre-existing cardiac abnormalities or electrolyte disturbances.
Special Warning
Klabid ER Tablet (Extended Release) 500 mg may be used in neonates and children in appropriate doses.
Acute Overdose
Signs & Symptoms : Ingestion of large amounts of Klabid ER Tablet (Extended Release) 500 mg can be expected to produce gastrointestinal symptoms. Symptoms of overdose may largely correspond to the profile of side effects.
Management: There is no specific antidote on overdose. Serum levels of Klabid ER Tablet (Extended Release) 500 mg can not be reduced by haemodialysis or peritoneal dialysis.
Storage Condition
Store in a cool and dry place, protected from light.
Innovators Monograph
You find simplified version here Klabid ER Tablet (Extended Release) 500 mg
Klabid ER Tablet (Extended Release) 500 mg contains Clarithromycin see full prescribing information from innovator Klabid ER Tablet (Extended Release) 500 mg Monograph, Klabid ER Tablet (Extended Release) 500 mg MSDS, Klabid ER Tablet (Extended Release) 500 mg FDA label
FAQ
What is Klabid ER Tablet (Extended Release) 500 mg used for?
Klabid ER Tablet (Extended Release) 500 mg is used to treat chest infections, such as pneumonia, skin problems such as cellulitis, and ear infections.It is also used to get rid of Helicobacter pylori, a bacteria that can cause stomach ulcers. Klabid ER Tablet (Extended Release) 500 mg used to treat various bacterial infections. This includes strep throat, pneumonia, skin infections, H. pylori infection, and Lyme disease, among others.
How safe is Klabid ER Tablet (Extended Release) 500 mg?
Klabid ER Tablet (Extended Release) 500 mg can be taken by adults and children.Klabid ER Tablet (Extended Release) 500 mg isn't suitable for some people. To make sure Klabid ER Tablet (Extended Release) 500 mg is safe for you, tell your doctor if you have allergic reaction to clarithromycin or any other medicines in the past.
Food and Drug Administration is advising caution before prescribing the antibiotic Klabid ER Tablet (Extended Release) 500 mg to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later.
How does Klabid ER Tablet (Extended Release) 500 mg work?
Klabid ER Tablet (Extended Release) 500 mg works by stopping the growth of bacteria. Antibiotics such as clarithromycin will not work for colds, flu, or other viral infections.
What are the common side effects of Klabid ER Tablet (Extended Release) 500 mg?
Common side effects of Klabid ER Tablet (Extended Release) 500 mg are include:
- feeling sick (nausea)
- diarrhoea and being sick (vomiting)
- losing your appetite.
- bloating and indigestion.
- headaches.
- difficulty sleeping (insomnia)
Is Klabid ER Tablet (Extended Release) 500 mg safe during pregnancy?
Klabid ER Tablet (Extended Release) 500 mg isn't normally recommended during pregnancy and while breastfeeding. But your doctor may prescribe it if the benefits of you taking it are greater than the risks.Klabid ER Tablet (Extended Release) 500 mg is the antibiotic most often used in pregnancy.
Is Klabid ER Tablet (Extended Release) 500 mg safe during breastfeeding?
Because of the low levels of Klabid ER Tablet (Extended Release) 500 mg in breastmilk and safe administration directly to infants, it is acceptable in nursing mothers. The small amounts in milk are unlikely to cause adverse effects in the infant.
Can I drink alcohol with Klabid ER Tablet (Extended Release) 500 mg?
You can drink alcohol while taking Klabid ER Tablet (Extended Release) 500 mg.
Can I drive after taking Klabid ER Tablet (Extended Release) 500 mg?
Avoid driving and doing other tasks or actions that call for you to be alert until you see how this medicine affects you.
When should be taken of Klabid ER Tablet (Extended Release) 500 mg?
Klabid ER Tablet (Extended Release) 500 mg usual to take Klabid ER Tablet (Extended Release) 500 mg twice a day once in the morning and once in the evening.
How quickly does Klabid ER Tablet (Extended Release) 500 mg work?
You should feel better within a few days. For skin problems such as cellulitis, you may have to take the medicine for about 7 days before you see any improvement.
How long does Klabid ER Tablet (Extended Release) 500 mg stay in my system?
Klabid ER Tablet (Extended Release) 500 mg stays in the body for a period of about 8 to 12 hours.
Is Klabid ER Tablet (Extended Release) 500 mg bad for the heart?
Klabid ER Tablet (Extended Release) 500 mg may increase the long term risk of heart problems and death in patients with heart disease.
Is Klabid ER Tablet (Extended Release) 500 mg safe for kidneys?
Klabid ER Tablet (Extended Release) 500 mg do not cause direct nephrotoxicity in general, but erythromycin and Klabid ER Tablet (Extended Release) 500 mg can influence kidney function secondary to interactions with other drugs.
Can I take Klabid ER Tablet (Extended Release) 500 mg long term?
This prospective study demonstrated that 6-month treatment with Klabid ER Tablet (Extended Release) 500 mg might be necessary to improve the clinical conditions of patients with DPB and Klabid ER Tablet (Extended Release) 500 mg could be safely used for a long term.
What happens if I miss a dose of Klabid ER Tablet (Extended Release) 500 mg?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose on Klabid ER Tablet (Extended Release) 500 mg?
Seek emergency medical attention.Overdose symptoms may include severe stomach pain, nausea, vomiting, or diarrhea.
Who should not take Klabid ER Tablet (Extended Release) 500 mg?
Your doctor will probably tell you not to take Klabid ER Tablet (Extended Release) 500 mg if you are taking one or more of these medications. Tell your doctor if you have or have ever had jaundice or other liver problems while taking Klabid ER Tablet (Extended Release) 500 mg. Your doctor will probably tell you not to take Klabid ER Tablet (Extended Release) 500 mg.
Is Klabid ER Tablet (Extended Release) 500 mg good for Covid?
Klabid ER Tablet (Extended Release) 500 mg seems likely that treatment of patients with COVID-19 with oral Klabid ER Tablet (Extended Release) 500 mg will substantially increase their anti-inflammatory properties and decrease the chances for development of severe respiratory failure.
What happen If I stop taking Klabid ER Tablet (Extended Release) 500 mg?
If you stop taking Klabid ER Tablet (Extended Release) 500 mg too soon, or skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics.
